European Pharmaceutical Review

MAY 7, 2024

percent compound annual growth rate (CAGR) between 2024 to 2029. billion by 2029. Approvals in the injectable drug delivery market In Nov 2023, the US Food and Drug Administration (FDA) approved the first and only obesity medication, Eli and Lilly’s Zepbound injection. The market is anticipated to value $1139.4

Vaccines 68

Vaccines Compounding Immunization FDA 68

Pharmaceutical Technology

APRIL 28, 2023

FDA approval follows the successful outcomes of the Sustain Forte trial (NCT03989232), the results of which displayed a superior reduction in HbA1c levels with once-weekly semaglutide 2.0mg, in comparison to once-weekly semaglutide 1.0mg, among individuals suffering from type 2 diabetes.

Dosage 52

Dosage Compounding Labelling FDA 52

Pharmaceutical Technology

JANUARY 10, 2023

billion in 2029, with drug sales almost doubling at a compound annual growth rate (CAGR) of 11.5%. billion in 2029, although its sales growth is likely to continue beyond 2029. GlobalData expects that the T2D market will see significant growth from 2019–29, with the 9MM having a total of $45.9

Labelling 52

Labelling Compounding Pharmaceutical Companies Pharmaceutical Companies 52

PharmaShots

FEBRUARY 22, 2023

Some of its FDA-approved competitors include: Patents7 Eli Lilly carries big expectations from Trulicity to boost its revenue. In the US, Trulicity is protected by a compound patent (2027) and by biologics data protection (2026). In the US, Trulicity is protected by a compound patent (2027) and by biologics data protection (2026).

Insurance 64

Insurance Compounding Dosage Communication 64

pharmaphorum

AUGUST 31, 2022

The sheer number of treatment candidates moving through the pipeline has seen a recent report by Polaris Market Research predicts that the market will grow at a compound annual growth rate of 17.0% from 2021 to 2029. FDA backing.

FDA 91

FDA Compounding Vaccines 91

The FDA Law Blog

DECEMBER 3, 2023

Manufacturers must also ensure that all electronic FDA listings and all NDC listings with the electronic database vendors used to process pharmacy claims, including information about discontinued drugs, are up to date for all applicable drug and selected drug NDCs. had Part D expenditures on or before August 16, 2022).

Labelling 105

Labelling Compounding Payment Processing Vaccines 105